Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed

TALPHERA, INC.

Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.
Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.
Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.
First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.
Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TALPHERA, INC. reported the three months ended December 31, 2023 results: revenue $0.3 million, net income $4.5 million, EPS $0.25 per basic and diluted share.

Period: the three months ended December 31, 2023
Revenue: $0.3 million
Net income: $4.5 million
EPS: $0.25 per basic and diluted share
Result: reported results

Exact text from the filing

● The cash and cash equivalents balance was $9.4 million as of December 31, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.3 million for the fourth quarter primarily represent the revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the prior

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-006817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.